Cargando…

Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs

Evidence for beneficial effects of corticotropin releasing hormone (CRH) antagonists in abdominal and pelvic organs is emerging in preclinical studies. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement a compilation of preclinical studies using CRH r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagán-Busigó, Joshua E., López-Carrasquillo, Jonathan, Appleyard, Caroline B., Torres-Reverón, Annelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916623/
https://www.ncbi.nlm.nih.gov/pubmed/35275963
http://dx.doi.org/10.1371/journal.pone.0264909
_version_ 1784668350479073280
author Pagán-Busigó, Joshua E.
López-Carrasquillo, Jonathan
Appleyard, Caroline B.
Torres-Reverón, Annelyn
author_facet Pagán-Busigó, Joshua E.
López-Carrasquillo, Jonathan
Appleyard, Caroline B.
Torres-Reverón, Annelyn
author_sort Pagán-Busigó, Joshua E.
collection PubMed
description Evidence for beneficial effects of corticotropin releasing hormone (CRH) antagonists in abdominal and pelvic organs is emerging in preclinical studies. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement a compilation of preclinical studies using CRH receptor antagonists as a treatment for abdominal and pelvic disease was carried out. The Animal Research: Reporting of In Vivo Experiments (ARRIVE) essential 10 guidelines were used to determine quality of the included studies. A total of 40 studies from the last 15 years studying irritable bowel syndrome, inflammatory bowel disease, endometriosis, enteritis, stress impact on gastrointestinal processes and exogenous CRH administration effects were included. Blockage of the CRH receptor 1 was mainly associated with beneficial effects while that of CRH receptor 2 worsened studied effects. However, time of administration, route of administration and the animal model used, all had an impact on the beneficial outcomes. Frequency of drugs administered indicated that astressin-2B, astressin and antalarmin were among the most utilized antagonists. Of concern, studies included were predominantly carried out in male models only, representing a gender discrepancy in preclinical studies compared to the clinical scenario. The ARRIVE score average was 13 with ~60% of the studies failing to randomize or blind the experimental units. Despite the failure to date of the CRH antagonists in moving across the clinical trials pipeline, there is evidence for their beneficial effects beyond mood disorders. Future pre-clinical studies should be tailored towards effectively predicting the clinical scenario, including reduction of bias and randomization.
format Online
Article
Text
id pubmed-8916623
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-89166232022-03-12 Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs Pagán-Busigó, Joshua E. López-Carrasquillo, Jonathan Appleyard, Caroline B. Torres-Reverón, Annelyn PLoS One Research Article Evidence for beneficial effects of corticotropin releasing hormone (CRH) antagonists in abdominal and pelvic organs is emerging in preclinical studies. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement a compilation of preclinical studies using CRH receptor antagonists as a treatment for abdominal and pelvic disease was carried out. The Animal Research: Reporting of In Vivo Experiments (ARRIVE) essential 10 guidelines were used to determine quality of the included studies. A total of 40 studies from the last 15 years studying irritable bowel syndrome, inflammatory bowel disease, endometriosis, enteritis, stress impact on gastrointestinal processes and exogenous CRH administration effects were included. Blockage of the CRH receptor 1 was mainly associated with beneficial effects while that of CRH receptor 2 worsened studied effects. However, time of administration, route of administration and the animal model used, all had an impact on the beneficial outcomes. Frequency of drugs administered indicated that astressin-2B, astressin and antalarmin were among the most utilized antagonists. Of concern, studies included were predominantly carried out in male models only, representing a gender discrepancy in preclinical studies compared to the clinical scenario. The ARRIVE score average was 13 with ~60% of the studies failing to randomize or blind the experimental units. Despite the failure to date of the CRH antagonists in moving across the clinical trials pipeline, there is evidence for their beneficial effects beyond mood disorders. Future pre-clinical studies should be tailored towards effectively predicting the clinical scenario, including reduction of bias and randomization. Public Library of Science 2022-03-11 /pmc/articles/PMC8916623/ /pubmed/35275963 http://dx.doi.org/10.1371/journal.pone.0264909 Text en © 2022 Pagán-Busigó et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pagán-Busigó, Joshua E.
López-Carrasquillo, Jonathan
Appleyard, Caroline B.
Torres-Reverón, Annelyn
Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
title Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
title_full Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
title_fullStr Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
title_full_unstemmed Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
title_short Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
title_sort beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916623/
https://www.ncbi.nlm.nih.gov/pubmed/35275963
http://dx.doi.org/10.1371/journal.pone.0264909
work_keys_str_mv AT paganbusigojoshuae beyonddepressionandanxietyasystematicreviewabouttheroleofcorticotropinreleasinghormoneantagonistsindiseasesofthepelvicandabdominalorgans
AT lopezcarrasquillojonathan beyonddepressionandanxietyasystematicreviewabouttheroleofcorticotropinreleasinghormoneantagonistsindiseasesofthepelvicandabdominalorgans
AT appleyardcarolineb beyonddepressionandanxietyasystematicreviewabouttheroleofcorticotropinreleasinghormoneantagonistsindiseasesofthepelvicandabdominalorgans
AT torresreveronannelyn beyonddepressionandanxietyasystematicreviewabouttheroleofcorticotropinreleasinghormoneantagonistsindiseasesofthepelvicandabdominalorgans